摘要
目的肺腺癌患者具有较高的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变发生率,吉非替尼治疗肺腺癌具有较好的疗效。本研究探讨吉非替尼单用及联合培美曲塞治疗EGFR突变晚期肺腺癌疗效及预后。方法选取2015-01-15-2018-01-15本院收治的EGFR突变型晚期肺腺癌患者90例为研究对象,按照性别、年龄组间匹配的原则分为观察组和对照组,各45例,对照组单用吉非替尼治疗,观察组在此基础上联合使用培美曲塞治疗,比较两组疗效及预后。结果观察组治疗有效率为66.67%,高于对照组的28.89%,χ~2=12.870,P<0.001;观察组疾病控制率为77.78%,高于对照组的48.89%,χ~2=8.086,P=0.004。观察组不良反应发生率为31.11%,对照组为20.00%,差异无统计学意义,χ~2=0.257,P=0.612。观察组中位无进展生存期(progression free survival,PFS)为12.59个月,对照组中位PFS为6.82个月,差异有统计学意义,P<0.001。结论吉非替尼联合培美曲塞治疗EGFR突变型晚期肺腺癌疗效较佳,疾病控制率较高,预后良好,不良反应可耐受。
OBJECTIVE Patients with lung adenocarcinoma have a higher incidence of epidermal growth factor receptor(EGFR)mutations,and gefitinib has a better effect on lung adenocarcinoma.This study explores the efficacy and prognosis of gefitinib alone and combined with pemetrexed in the treatment of advanced lung adenocarcinoma with EGFR mutation.METHODS A total of 90 patients with EGFR mutant advanced lung adenocarcinoma admitted in our hospital from January 15th,2015 to January 15th,2018 were selected as the research object,and were divided into observation group and control group according to the principle of matching between gender and age,45 cases in each group,The control group was treated with gefitinib alone,and the observation group was treated with pemetrexed and gefitinib.The efficacy and prognosis of the two groups were compared.RESULTS The treatment effective rate of the observation group was 66.67%,which was higher than that of the control group 28.89%,χ~2=12.870,P<0.001.The disease control rate of the observation group was 77.78%,which was higher than that of the control group(48.89%),χ~2=8.086,P=0.004.The incidence of adverse reactions in the observation group was 31.11%,and that in the control group was20.00%.There was no statistically significant difference between the two groups,χ~2=0.257,P=0.612.The median progression free survival(PFS)of the observation group was 12.59 months,and the median PFS of the control group was6.82 months,the difference was statistically significant,P<0.001.CONCLUSIONS Gefitinib combined with pemetrexed was better for the treatment of EGFR mutant advanced lung adenocarcinoma.The disease control rate was higher,the prognosis was good,and adverse reactions were tolerable.
作者
王杰
汪海新
李山岭
WANG Jie;WANG Hai-xin;LI Shan-ling(Department of Oncology,Army Hospital of the 83rd Army of the People's Liberation Army,Xinxiang453000,P.R.China)
出处
《社区医学杂志》
2020年第10期740-743,共4页
Journal Of Community Medicine
关键词
肺腺癌
表皮生长因子受体
吉非替尼
培美曲塞
疗效
预后
lung adenocarcinoma
epidermal growth factor receptor
gefitinib
pemetrexed
efficacy
prognosis
